This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Oramed Pharmaceuticals To Present Results Of Its Key Clinical Studies Of Oral Insulin In Type 1 Diabetes Patients At The GTC Diabetes Summit, Boston, MA; April 29-30, 2013

Stocks in this article: ORMP

JERUSALEM, April 29, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ( http://www.oramed.com), a developer of oral delivery systems of drugs currently administered by injection, announced today that its abstract, entitled "Oral insulin capsules toward management of Type 1 diabetes mellitus," will be presented at the Global Technology Community Diabetes Summit 2013. The poster will be presented today, April 29 th, by Dr. Miriam Kidron, Oramed's Chief Scientific Officer, between 5:00pm-7:00pm EDT during the poster session and evening reception in the Ballroom Foyer of the Hyatt Regency Hotel.

The work summarizes the results of Oramed's key clinical studies assessing the safety and efficacy of its oral insulin formulation (ORMD-0801) in patients with Type 1 diabetes (T1DM) and in a subpopulation of T1DM patients who experience frequent and unpredictable swings in their blood sugar levels.  ORMD-0801 was safe and well tolerated and effectively kept blood sugar levels in check, when administered before meals.  In addition, the blood sugar readings of unstable T1DM patients more frequently fell within the normal range, when compared to those of the pretreatment monitoring sessions. The presented results demonstrate that Oramed's technology effectively delivers insulin without compromising its bioactivity, and serve as an impetus to realize the therapeutic potential of ORMD-0801 in regulating T1DM.

The poster will be available on Oramed's website later this evening, following the poster presentation time, at: http://oramed.com/index.php?page=13

About The  Global Technology Community  Diabetes Summit

The GTC Diabetes Summit is the only diabetes conference that provides delegates the opportunity to facilitate discussions and collaborations among affiliations (industry, academia, government) that can lead to the advancement of therapeutics and development of drugs/treatments for diabetes, and hopefully one day a cure. In addition the conference will provide updated educational research on various novel targets, therapeutics, developments, and technologies; regulatory guidance; case studies on successful and/or unsuccessful clinical trials; and other relevant insights that can help delegates advance their own research and therapeutics. 

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs